Loading data for INO — first visit, this takes a few seconds.

Alerta

Inovio Pharmaceuticals In... (INO)

NasdaqCM: INO · Precio en tiempo real · USD

1.20

+0.05 (4.35%)

Al cierre: Aug 18, 2026, 8:00 PM

4.35% (1D)

No hay datos disponibles

Precio de compra	1.01
Capitalización de mercado	123.99M
Ingresos (TTM)	n/a
Beneficio neto (TTM)	-67.43M
Beta	n/a
EPS (TTM)	-1.03
Ratio PER (TTM)	n/a
Adelante PE	-2.73
P/B (TTM)	28.57
P/S (TTM)	n/a
Earnings Date	Nov 10, 2026

Precio de venta	1.35
Volumen	4,719,596
Volumen medio (20D)	3,072,477
Abierto	1.14
Anterior Cerrar	1.15
Rango del día	1.07 - 1.22
Rango de 52 semanas	0.56 - 2.98
analista	n/a
Precio objetivo	n/a
Dividendos	n/a
Fecha ex dividendo	n/a

Acerca de INO

Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses SynCon, to help engineer precisely designed plasmid DNA plasmids, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. The com...

[Leer más]

Industria Biotechnology

Sector Healthcare

IPO Fecha Dec 8, 1998

Empleados 112

Bolsa de Valores NasdaqCM

Símbolo bursátil INO

Sitio web https://www.inovio.com

Perfil completo de la empresa

Desempeño financiero

En 2025, los ingresos de Inovio Pharmaceuticals fueron 65.34K, una disminución de -69.99% en comparación con 217.76K del año anterior. Las ganancias fueron -84.95M, una disminución de -20.8%.

Estados financieros

Sorpresa de resultados

Inovio Pharmaceuticals ha publicado sus resultados trimestrales en Aug 12, 2026:

Ingresos de $0 falla las estimaciones por $0, con -100.00% Disminución interanual.

EPS de -0.24 falla las estimaciones por 0.00, con 60.66% Crecimiento interanual.

Próxima publicación de resultados

Está previsto que Inovio Pharmaceuticals Inc. publique sus resultados el Nov 10, 2026, durante el horario de mercado.
Los analistas proyectan ingresos de ... Actualizar

Noticias

5 días hace · GuruFocus.com

Inovio Pharmaceuticals Inc (INO) (Q2 2026) Earnings Call Highlights: INO-3107 on Track for ...

Inovio reports a narrowed net loss and strong progress toward a potential INO-3107 launch, while securing funding through late Q1 2027.

6 días hace · Moby

Inovio Pharmaceuticals, Inc. Q2 2026 Earnings Call Summary

Moby summary of Inovio Pharmaceuticals, Inc.'s Q2 2026 earnings call

6 días hace · MarketBeat

Inovio Pharmaceuticals Q2 Earnings Call Highlights

Inovio Pharmaceuticals (NASDAQ:INO) said the U.S. Food and Drug Administration has completed several key steps in its review of the company’s biologics license application for INO-3107, an investigati...

2 meses hace · MarketBeat

Inovio Pharmaceuticals Shareholders Back Board as INO-3107 FDA Review Advances

Inovio Pharmaceuticals (NASDAQ:INO) shareholders approved all proposals presented at the company’s 2026 annual meeting, including the election of eight directors and the ratification of Ernst & Young ...

2 meses hace · Stocktwits

INO Stock Edges Up After Hours As Partner Reports Success In Cervical Dysplasia Trial

The study showed that the treatment helped reverse precancerous changes in the cervix and clear the high-risk HPV virus that causes them in many patients.

Página 1 de 2